Switching Single-Inhaler Triple Therapy in COPD
Trelegy Ellipta is administered once daily, while Breztri Aerosphere is administered twice daily as a fixed-dose triple inhaler. [1][2] A switch is performed by stopping Trelegy and initiating Breztri at the next scheduled maintenance dose time, using Breztri’s labeled dosing and re-teaching inhaler technique because device type differs. [1][2][3][4]
Medication Dosing Conversion
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is prescribed as 1 inhalation once daily for COPD. [1] Breztri Aerosphere (budesonide/glycopyrrolate/formoterol) is prescribed as 2 inhalations twice daily (morning and evening). [2]
Switch Timing Strategy
Trelegy Ellipta should be discontinued when the next dose of controller therapy is due. [1] Breztri Aerosphere should be started at that time using 2 inhalations in the morning and 2 inhalations in the evening per labeling. [2] Overlapping doses should be avoided by using the next scheduled maintenance dosing time for Breztri initiation. [1][2]
Inhaler Device Technique Re-Counseling
Device technique should be re-counseled at the time of switching because Trelegy is delivered via a dry powder inhaler and Breztri is delivered via a pressurized metered-dose inhaler. [3][4] Inhaler technique and medication regimen should be reviewed at follow-up and at each visit to support correct use and adherence. [4]
Rescue Medication and Exacerbation Plan Continuation
A short-acting bronchodilator for rescue treatment should be continued under the existing COPD action plan while controller therapy is transitioned. [4] Exacerbation instructions should remain unchanged unless specifically modified after assessment. [4]
Common Switching Pitfalls
Administering Breztri on a once-daily schedule is a common error because labeled maintenance dosing is twice daily. [2] Using Trelegy inhalation technique with Breztri (or vice versa) is a common error because the devices differ by inhalation method. [3][4] Failure to re-counsel inhaler technique increases the risk of incorrect dosing delivery after the switch. [4]
Treatment Monitoring After Switch
Clinical monitoring for symptom control and adverse effects should occur after switching controller inhalers. [4] Inhaler technique should be reassessed if symptom worsening or inadequate response is reported. [4]
Safety and Administration Considerations
Breztri administration should follow labeled technique and dosing frequency to reduce local steroid adverse effects risk associated with inhaled corticosteroid use. [2] Trelegy administration should follow labeled dosing frequency for COPD to maintain consistent controller therapy. [1]